Abstract
The present invention relates to an intervention strategy in the prevention or treatment of a subject having autoimmune disease. The intervention preferably relates to administration of a Desu/fovibrio species, wherein the Desu/fovibrio species is preferably chosen from the group consisting of Desu/fovibrio piger, Desu/fovibrio fairfie/densis, Desu/fovibrio desu/furicans, desulfovibrio indonensis, Desu/fovibrio alaskensis, Desu/fovibrio vulgaris, Desu/fovibrio vietnamensis and Desu/fovibrio gigas. Alternatively, the intervention strategy relates to administration of a chloro-, fluoro-, or bromo-substituted tryptophan, preferably 6- bromotryptophan, and/or a mono- or di-fatty acid substituted glycerol phosphocholine (GPC), preferably chosen from the group consisting of 1-myristoyl-2-arachidonoyl-glycero- phosphocholine (MA-GPC) and 1-arachidonoyl-glycero-phosphocholine (A-GPC), or any derivative or functional equivalent of these.
| Original language | English |
|---|---|
| Patent number | NL2025021 |
| Priority date | 28/02/20 |
| Publication status | Published - 14 Oct 2021 |